Tesamorelin (10mg)

Description

Tesamorelin is a stabilized synthetic analogue of human growth hormone-releasing hormone (GHRH) in which the N-terminus is conjugated to trans-3-hexenoic acid. This modification dramatically improves metabolic stability versus native GHRH(1-44) while preserving full GHRH receptor agonist activity. Tesamorelin received FDA approval (Egrifta) in 2010 for HIV-associated lipodystrophy, making it one of the few research peptides with a well-established clinical pharmacological profile.

Why Researchers Select Tesamorelin

Tesamorelin’s unique value is its extensive clinical pharmacokinetic database — absorption, distribution, IGF-1 stimulation kinetics, and metabolic effects have been characterized in large human trials — providing translational researchers with a validated human pharmacology reference point. In laboratory research, it is used to study visceral adipose tissue (VAT) metabolism (Tesamorelin significantly reduced VAT in clinical trials), GHRH receptor signaling under improved stability conditions, and GH/IGF-1 axis activation with more consistent receptor occupancy than short-acting GHRH analogues.

Common Research Applications

• GHRH receptor agonism with validated clinical pharmacokinetics
• Visceral adipose tissue metabolism and lipodystrophy models
• GH/IGF-1 axis activation under sustained GHRH signaling
• GHRH analogue stability and receptor occupancy studies
• Translational research bridging preclinical and clinical GH axis data

Molecular Profile

• MW: ~5,135 g/mol | CAS: 218949-48-9 | Modification: trans-3-hexenoic acid N-conjugate | Purity: ≥98% HPLC

For Research Use Only. Not for human or veterinary use.